Supplementary Table 1. All Integration Sites with 2 or More Breakpoints in the Same or Different Samples

A. Group 1A Fiebig III-IV					
Patient identifier	**Clonal integration site**	**Pre-ART sample**	**1st sample on ART**	**2nd sample on ART**	**Final sample on ART**
CH 83-1	chr19+9258493	2			
CH 83-1	chr19+44073330				2
CH 83-1	chr22-50214458				2
CH 84-4	Chr2+21000871	2			
CH 84-4	Chr4+2872637	2			
PITT 001	chr8-33353611	2			
PITT 001	chr1-150377592		1		1
PITT 001	chr16-67111038		1		1
PITT 001	chr17+62637086		1		1
PITT 001	chr15-42751324				3
PITT 001	chr11+128217390				2
PITT 001	chr9-132716561				2

Supplementary Table 1, Continued

B. Fiebig IV/V-V					
Patient identifier	**Clonal integration site**	**Pre-ART sample**	**1st sample on ART**	**2nd sample on ART**	**Final sample on ART**
CH 62-1	chr9-127979468	4			
CH 62-1	chr22+46112754	3			
CH 62-1	chr1-25782953	2			
CH 62-1	chr11-67116156	2			
CH 62-1	chr11+118695247	2			
CH 62-1	chr12-100682913	2			
CH 62-1	chr2+149416626	2			
CH 62-1	chr21-40593997	2			
CH 62-1	chr21+46039130	2			
CH 62-1	chr3-196308839	2			
CH 62-1	chr3-48094048	2			
CH 62-1	chr6+43177807	2			
CH 62-1	chr7-105743766	2			
CH 62-1	chr8-145131710	2			
CH 62-1	chr9-103800000	2			
CH 62-1	chr17+69468843	1			3
CH 62-1	chr22+20045150	1			1
CH 62-1	chr3+7721786	1			1
CH 62-1	chr4-42079723	1			1
CH 62-1	chr20-5949450	1		3	
CH 62-1	chr11+11902735			18	11
CH 62-1	chr2-113378864		1	2	4
CH 62-1	chr17+41266738			4	3
CH 62-1	chr9+110250443				3
CH 62-1	chr15-41611199				2
CH 62-1	chr2-170744143				2
CH 62-1	chr3-130431602				2
CH 62-1	chr4-76567548				2
CH 62-1	chr5+131908038			4	2
CH 62-1	chr1+144926752			1	1

Supplementary Table 1, Continued

B. Fiebig IV/V-V					
Patient identifier	**Clonal integration site**	**Pre-ART sample**	**1st sample on ART**	**2nd sample on ART**	**Final sample on ART**
CH 62-1	chr10+24896384			1	1
CH 62-1	chr3-5015578			1	1
CH 62-1	chr4+110588787			1	1
CH 62-1	chr1-32496405			2	
CH 62-1	chr2+64359841			2	
CH 62-1	chr6-139459663		1	2	
CH 62-1	chr6-90758206			2	
CH 62-1	chr8+21941200			2	
CH 68-5	chr3+37402201	2			
CH 68-5	chr10-6557761			1	2
CH 91-4	chr10-104035009	2			
CH 91-4	chr4-143235363	2			
CH 91-4	chr16+2268635	2			
CH 91-4	chr22-31805541			2	
CH 91-4	chr5-157077293			2	
CH 98-6	chr12-940948	2			2
CH 98-6	chr16-67068330	2			1
CH 98-6	chr11+33767372				2
CH 98-6	chr2+205706236		1		2
CH 98-6	chr4-40118668		1		1
CH 98-6	chr4+78709265		1		1
CH 98-6	chr3-184605768		2		

Supplementary Table 1, Continued

C. Fiebig V/VI-VI					
Patient identifier	**Clonal integration site**	**Pre-ART sample**	**1st sample on ART**	**2nd sample on ART**	**Final sample on ART**
IDFU-192	chr19+10245238	3			
IDFU-192	chr10-76140002	2			
IDFU-192	chr1+33256644	2			
IDFU-192	chr11-65873638	2			
IDFU-192	chr12-95388674	2			
IDFU-192	chr14+55455295	2			
IDFU-192	chr16+90058505	2			
IDFU-192	chr6+42244089				16
IDFU-192	chr9+114789092				10
IDFU-192	chr2-98573687				7
IDFU-192	chr15-40902811				5
IDFU-192	chr16-29178691				5
IDFU-192	chr16-3555885				5
IDFU-192	chr10+4231431				3
IDFU-192	chr11+116779643				3
IDFU-192	chr17-73332709				3
IDFU-192	chr19+50081595				3
IDFU-192	chr2+30570802				3
IDFU-192	chr9-3571470				3
IDFU-192	chr12+56341242				2
IDFU-192	chr13+32142432				2
IDFU-192	chr16-56280725				2
IDFU-192	chr17+1274949				2
IDFU-192	chr17+5243828				2
IDFU-192	chr17+57764861				2
IDFU-192	chr19-5600470				2
IDFU-192	chr19+16675039				2
IDFU-192	chr2+9728205				2
IDFU-192	chr9-130228742				2
IDFU-194	chr5+176667385	3			

Supplementary Table 1, Continued

C. Fiebig V/VI-VI					
Patient identifier	**Clonal integration site**	**Pre-ART sample**	**1st sample on ART**	**2nd sample on ART**	**Final sample on ART**
IDFU-194	chr1+46778593				2
AVBIO2-14	chr1-160428287				20
AVBIO2-14	chr22-50670666				11
AVBIO2-14	chr11+64538784				10
AVBIO2-14	chrX+48770803				7
AVBIO2-14	chr17-1336580				4
AVBIO2-14	chr19+36601449				4
AVBIO2-14	chr11-62584548				3
AVBIO2-14	chr11+118896188				3
AVBIO2-14	chr12-92815754				3
AVBIO2-14	chr16+89820040				3
AVBIO2-14	chr19-13871733				3
AVBIO2-14	chr19-54696726				3
AVBIO2-14	chr3+196629283				3
AVBIO2-14	chr5-176567104				3
AVBIO2-14	chr6-33629574				3
AVBIO2-14	chr6-97677185				3
AVBIO2-14	chr1-27805441				2
AVBIO2-14	chr16+68204582				2
AVBIO2-14	chr16+81059453				2
AVBIO2-14	chr2+169071548				2
AVBIO2-14	chr20-34315551				2
AVBIO2-23	chr12-9128078	2			
AVBIO2-23	chr17-79529201	2			
AVBIO2-23	chrX+153000321	2			
AVBIO2-23	chr14+22462009				8
AVBIO2-23	chr13-28228319				3
AVBIO2-23	chr19-49101446				3

Supplementary Table 1, Continued

C. Fiebig V/VI-VI					
Patient identifier	**Clonal integration site**	**Pre-ART sample**	**1st sample on ART**	**2nd sample on ART**	**Final sample on ART**
AVBIO2-23	chr19+16464466				3
AVBIO2-23	chr6-90721696				3
AVBIO2-23	chr19+50080861				2
AVBIO2-23	chr6-31523304				2
AVBIO2-04	chr19-18389190				9
AVBIO2-04	chr17-43118025				7
AVBIO2-04	chr1+150196025				5
AVBIO2-04	chr14-70085442				5
AVBIO2-04	chr22-40853141				4
AVBIO2-04	chr11-65269159				3
AVBIO2-04	chr6-90748958				3
AVBIO2-04	chr10-76598793				2
AVBIO2-04	chr16+3556717				2
AVBIO2-04	chr17-26444407				2
AVBIO2-04	chr17-40384674				2
AVBIO2-04	chr19-1246428				2
AVBIO2-04	chr19-17520553				2
AVBIO2-04	chr2-231098370				2
AVBIO2-04	chr20-62343439				2
AVBIO2-04	chr22-37551672				2

Supplementary Table 1, Continued

D. Chronic Infection

Patient identifier	Clonal integration site	Pre-ART sample	1st sample on ART	2nd sample on ART	Final sample on ART
AVBIO2-21	chr7-139826967	3			1
AVBIO2-21	chr16+3676180	2			5
AVBIO2-21	chr6-35556375	2			
AVBIO2-21	chr22-30515408				62
AVBIO2-21	chr11-46851472				7
AVBIO2-21	chr11+18515986				3
AVBIO2-21	chr12-66709123				3
AVBIO2-21	chr1+22072665				2
AVBIO2-21	chr17+38793595				2
AVBIO2-21	chr17+4596357				2
AVBIO2-21	chr2+128279836				2
AVBIO2-21	chr9+98654262				2
AVBI02-08	chr1-109496930	1			1
AVBIO2-18	chr6+135524982	2			
AVBIO2-18	chr19-8527192				18
AVBIO2-18	chr5+138977164				13
AVBIO2-18	chr21+45295997				6
AVBIO2-18	chr16-68130899				5
AVBIO2-18	chr17-40404703				3
AVBIO2-18	chr3+49375155				3
AVBIO2-18	chr6+11716795				3
AVBIO2-18	chrX-48842188				3
AVBIO2-18	chr12-107353077				2
AVBIO2-18	chr12-46259128				2
AVBIO2-18	chr12+110585436				2
AVBIO2-18	chr12+121228481				2
AVBIO2-18	chr12+47747147				2
AVBIO2-18	chr16+14309452				2

Supplementary Table 1, Continued

D. Chronic Infection					
Patient identifier	**Clonal integration site**	**Pre-ART sample**	**1st sample on ART**	**2nd sample on ART**	**Final sample on ART**
AVBIO2-18	chr17+79510021				2
AVBIO2-18	chr3+195099387				2
AVBIO2-102	chr19-10556837				4
AVBIO2-03	chr15+75815501				3
AVBIO2-03	chr17-40412083				3
AVBIO2-03	chr17-40419263				3
AVBIO2-03	chr17+75832295				3
AVBIO2-03	chr1-24723449				2
AVBIO2-03	chr12+112474797				2
AVBIO2-03	chr19-50332546				2
AVBIO2-03	chr22-41547499				2
AVBIO2-03	chr5-138964471				2

*All the sites with multiple breakpoints. The location and orientation of the integration are given as based on the hg19 build of the human genome sequence. The table also lists the number of times the integration site was recovered from each of the samples analyzed for that donor. Sites that were confirmed as clones are shown in yellow. Clones that were present in a pre-therapy sample and also present in at least one of the on-ART Samples are highlighted in green. Pretherapy sites that could have been due to cell DNA synthesis post integration are not highlighted.

Supplementary Table 2. Cell-Associated HIV DNA, Integration Sites, and Clones in PBMC from Early-Treated Patients (Cohort 1) with Multiple on-ART Sample

Pre-ART samples					First on-ART samples			Second on-ART samples			Final On-ART samples			
Stage (PID)	HIV DNA*	Cells (10^6) used for ISA	Unique integration sites	Clones**	HIV DNA*	Unique Integration sites	Clones	HIV DNA*	Unique integration sites	Clones	HIV DNA* (fold decline from pre-ART)	Cells (10^6) used for ISA	Unique integration sites	Clones detected (number identical to pre-ART clones)
FIII (84-4)	1,700	1.5	176	0	160	4	0	50	0	0	4 (425)	1.5	4	0
FIV AHI-001	14,000	1.5	149	0	230	58	3	ND	ND	ND	ND	1.5	58	6
FIV/V (62-1)	18,000	4.5	709	14	2,000	9	2	1,250	116	14	380 (47)	1.5	114	17 (4)
FV (68-5)	5,600	1.5	366	1	2100	33	0	1,250	12	1	120 (47)	1.5	15	1 (0)
FV (91-4)	4,800	4.5	416	3	230	21	0	120	49	2	34 (141)	1.5	63	0
FV (98-6)	1,900	3	179	2	200	53	4	ND	ND	ND	35 (54)	1.5	86	6 (2)

* per 10^6 PBMC.
** Confirmed clones as in Table 2.

Supplementary Table 3*

Clone size	Number of integration sites recovered				
	100	**500**	**1,000**	**5,000**	**10,000**
10,000	0.000	0.001	0.005	0.090	0.264
50,000	0.001	0.026	0.090	0.713	0.960
100,000	0.005	0.090	0.264	0.960	1.000
500,000	0.090	0.713	0.960	1.000	1.000
1,000,000	0.264	0.960	1.000	1.000	1.000
5,000,000	0.960	1.000	1.000	1.000	1.000
10,000,000	1.000	1.000	1.000	1.000	1.000

*This table shows the calculated probability of detecting a clone, using integration site analysis, based on the assumptions listed in Materials and Methods, on the size of the clone, and the number of integration sites recovered.